{"id":"etn-mtx","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor-alpha, a key inflammatory cytokine. Methotrexate is a disease-modifying antirheumatic drug (DMARD) that inhibits dihydrofolate reductase and reduces cellular proliferation and immune activation. The combination provides synergistic anti-inflammatory and immunosuppressive effects.","oneSentence":"ETN+MTX is a combination therapy of etanercept (TNF inhibitor) and methotrexate that suppresses tumor necrosis factor and reduces immune-mediated inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:45:59.730Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Other TNF-responsive inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT04118556","phase":"PHASE2","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","status":"RECRUITING","sponsor":"Mats Remberger","startDate":"2021-12-01","conditions":"GVHD, Acute","enrollment":50},{"nctId":"NCT03728478","phase":"PHASE3","title":"STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS","status":"RECRUITING","sponsor":"Istituto Giannina Gaslini","startDate":"2019-05-29","conditions":"Oligoarthritis, Juvenile, Polyarthritis, Juvenile, Rheumatoid Factor Negative","enrollment":260},{"nctId":"NCT02913261","phase":"PHASE3","title":"Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-03-10","conditions":"Corticosteroid Refractory Acute Graft vs Host Disease","enrollment":310},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT02374021","phase":"PHASE4","title":"Treatments Against RA and Effect on FDG-PET/CT","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-07","conditions":"Arthritis, Rheumatoid","enrollment":159},{"nctId":"NCT01303874","phase":"PHASE4","title":"Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE)","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2006-09","conditions":"Rheumatoid Arthritis, Inflammatory Arthritis","enrollment":112},{"nctId":"NCT03775824","phase":"","title":"Faecal Analyses in Rheumatoid Arthritis Therapy","status":"COMPLETED","sponsor":"Region Skane","startDate":"2016-08-01","conditions":"Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT02715908","phase":"PHASE3","title":"A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX)","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2016-04","conditions":"Rheumatoid Arthritis","enrollment":148},{"nctId":"NCT01764997","phase":"PHASE3","title":"An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate","status":"TERMINATED","sponsor":"Sanofi","startDate":"2013-04","conditions":"Rheumatoid Arthritis","enrollment":776},{"nctId":"NCT01558089","phase":"","title":"Good EULAR Response In Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-03","conditions":"Rheumatoid Arthritis","enrollment":76},{"nctId":"NCT02878161","phase":"PHASE4","title":"Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From \"Real World\"","status":"UNKNOWN","sponsor":"Fen Li","startDate":"2016-01","conditions":"Rheumatoid Arthritis","enrollment":240},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT00848354","phase":"PHASE4","title":"Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-06","conditions":"Rheumatoid Arthritis","enrollment":429},{"nctId":"NCT02357069","phase":"PHASE3","title":"A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"UNKNOWN","sponsor":"LG Life Sciences","startDate":"2015-02","conditions":"Arthritis, Rheumatoid","enrollment":372},{"nctId":"NCT00688103","phase":"PHASE4","title":"Efficacy and Safety of Etanercept in Active RA Despite Methotrexate Therapy in Japan","status":"COMPLETED","sponsor":"Japan Biological Agent Study Integrated Consortium","startDate":"2005-06","conditions":"Rheumatoid Arthritis","enrollment":151},{"nctId":"NCT00298272","phase":"PHASE2","title":"Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Biogen","startDate":"2006-05","conditions":"Rheumatoid Arthritis","enrollment":54},{"nctId":"NCT01004432","phase":"PHASE3","title":"Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2009-12","conditions":"Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases","enrollment":433},{"nctId":"NCT00259610","phase":"PHASE4","title":"Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2004-05","conditions":"Rheumatoid Arthritis","enrollment":755},{"nctId":"NCT01557322","phase":"","title":"Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-10","conditions":"Rheumatoid Arthritis","enrollment":1754},{"nctId":"NCT00115219","phase":"PHASE4","title":"Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-05","conditions":"Rheumatoid Arthritis","enrollment":200},{"nctId":"NCT00706797","phase":"PHASE4","title":"Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-09","conditions":"Rheumatoid Arthritis","enrollment":141},{"nctId":"NCT00931957","phase":"NA","title":"Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2010-10","conditions":"Behcet Syndrome, Uveal Disease","enrollment":80},{"nctId":"NCT00764725","phase":"PHASE4","title":"Comparison of MTX+Anti-TNF to MTX+Conventional DMARDs in Patients With Early Rheumatoid Arthritis (RA) Who Failed MTX Alone (SWEFOT)","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":487}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["etanercept and methotrexate"],"phase":"marketed","status":"active","brandName":"ETN+MTX","genericName":"ETN+MTX","companyName":"Japan Biological Agent Study Integrated Consortium","companyId":"japan-biological-agent-study-integrated-consortium","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ETN+MTX is a combination therapy of etanercept (TNF inhibitor) and methotrexate that suppresses tumor necrosis factor and reduces immune-mediated inflammation. Used for Rheumatoid arthritis, Other TNF-responsive inflammatory conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}